glipizide has been researched along with pyrazines in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gwilt, M; Henderson, CG; Orme, J; Rourke, JD | 2 |
| Feng, Y; Howard, AD; Li, C; Li, Z; Moller, DE; Mu, J; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Meininger, G; Nauck, MA; Sheng, D; Stein, PP; Terranella, L | 1 |
| Bloomgarden, ZT; Inzucchi, SE | 1 |
| Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D | 1 |
| Eiermann, GJ; Feng, Y; Howard, AD; Li, C; Li, Z; Mu, J; Petrov, A; Roy, RS; Thornberry, NA; Woods, J; Zhang, BB; Zhou, YP; Zhu, L; Zycband, E | 1 |
| Amatruda, JM; Davies, MJ; Kaufman, KD; Nauck, M; Seck, T; Sheng, D; Stein, PP; Sunga, S | 1 |
| Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Seck, TL; Sisk, CM; Wang, H; Williams-Herman, DE | 1 |
| Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM | 1 |
| Davies, MJ; Ferrante, SA; Goldstein, BJ; Kaufman, KD; Krobot, KJ; Meininger, GE; Seck, T; Williams-Herman, D | 1 |
| Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM | 1 |
5 trial(s) available for glipizide and pyrazines
| Article | Year |
|---|---|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Protease Inhibitors; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2007 |
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Placebos; Pyrazines; Renal Insufficiency, Chronic; Severity of Illness Index; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Young Adult | 2010 |
Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Weight Gain | 2011 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles | 2013 |
8 other study(ies) available for glipizide and pyrazines
| Article | Year |
|---|---|
Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro.
Topics: 4-Aminopyridine; Animals; Anti-Arrhythmia Agents; Benzothiazoles; Calcium Channel Blockers; Disease Models, Animal; Glipizide; Glyburide; Guinea Pigs; In Vitro Techniques; Male; Myocardial Ischemia; Piperidines; Potassium; Potassium Channels; Pyrazines; Pyridines; Sympatholytics; Thiazoles; Ventricular Fibrillation | 1992 |
K(+)-channel blockers and coronary vasoconstriction in guinea-pig perfused hearts in-vitro.
Topics: 4-Aminopyridine; Adenosine Triphosphate; Animals; Coronary Vessels; Glipizide; Glyburide; Guinea Pigs; In Vitro Techniques; Male; Perfusion; Phentolamine; Potassium Channels; Pyrazines; Pyridines; Vasoconstriction | 1993 |
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Disease Models, Animal; Dyslipidemias; Glipizide; Hypoglycemic Agents; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Mice, Inbred ICR; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2006 |
New treatments for diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin | 2007 |
Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Triazoles | 2008 |
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Ki-67 Antigen; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Pyrazines; Sitagliptin Phosphate; Triazoles; Triglycerides | 2009 |
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Topics: Adult; Aged; Aged, 80 and over; Calibration; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Sitagliptin Phosphate; Time Factors; Triazoles | 2012 |